9 news items
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI
3 Jun 24
compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds approved for the treatment of cancer. XPOVIO functions by selectively
Karyopharm to Participate at the Jefferies Global Healthcare Conference
KPTI
29 May 24
. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
KPTI
8 May 24
that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer
74bnd0rf3wa0r5x0dx6al0dn2
KPTI
2 May 24
, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis
9dca5v9tse59t3 n7dnb8h79oy37h7euj47v
KPTI
24 Apr 24
Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting
kqjy2tdgl2seauozlv9gsqivla4g
KPTI
24 Apr 24
Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding
8497m66g i95fijslpx4eo0ygs
KPTI
1 Apr 24
, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental
- Prev
- 1
- Next